Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 7/20 | 0.50 |
| ▸ | SLC5A2 | P31639 | 7/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382747 | 1.00 | SLC5A1 (0.50) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL30383241 | 0.90 | SLC5A1 (0.50) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL12807948 | 0.90 | SLC5A1 (0.50) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL25223578 | 0.90 | SLC5A1 (0.50) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL30382841 | 0.90 | SLC5A1 (0.50) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| Ethane SCHEMBL25223359 | 0.90 | SLC5A1 (0.49) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL25201218 | 0.82 | SLC28A3 (0.64) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL30384588 | 0.82 | SLC28A3 (0.64) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL25208547 | 0.82 | SLC28A3 (0.64) | SLC5A1SLC5A2AKR1B1DPP4GAA | |
| SCHEMBL13553044 | 0.81 | SLC28A3 (0.66) | SLC5A1SLC5A2SLC28A3MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | SLC5A1 3752/4885SLC5A2 4208/4885AKR1B1 2220/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | SLC5A1 4485/4885SLC5A2 4756/4885AKR1B1 2215/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | SLC5A1 4485/4885SLC5A2 4756/4885AKR1B1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.